Imeglimin: a first-in-class oral medication with a unique mechanism of action targeting mitochondrial bioenergetics

Wednesday, 18 September 2019, 12:00 - 13:00, Ochoa Hall

Chair: R.A. DeFronzo, US

R.A. DeFronzo, US: The role of mitochondrial dysfunction in the pathophysiology of diabetes

J. Dubourg, FR: Clinical evidence to support the safety and efficacy of imeglimin in various populations of patients with type 2 diabetes